-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Subclinical atrial fibrillation (SCAF) is usually asymptomatic but harmful
.
In addition to clinical stratification models, plasma biomarkers of atrial fibrillation-related processes may improve its risk prediction
Recently, the heart blood vessels published a research article on the disease areas authoritative magazine JAHA, in patients with cardiac implantable electronic devices, researchers aimed to assess the combination of homocysteine and uric acid (UA) biomarkers to distinguish between SCAF Performance of high-risk patients
.
Researchers continuously recruited 1,224 patients in Dalian, China from January 2013 to December 2019 to evaluate SCAF in patients with cardiac implantable electronic devices
.
Clinical data and blood samples come from patients with atrial high frequency seizures> 6 minutes
The researchers found that homocysteine and UA biomarkers were significantly different in SCAF and SCAF-free patients
.
In a multivariate Cox regression analysis with potential confounding factors, elevated homocysteine and UA biomarkers were significantly associated with an increased risk of SCAF
guide
It can be seen that homocysteine and UA biomarkers are closely related to SCAF
.
By adding selected biomarkers, the prediction performance of the European Society of Cardiology model for SCAF has been improved
Homocysteine and UA biomarkers are closely related to SCAF
Original source:
Shihao Wang,et al.